BELITE BIO Q1 FY26 earnings call BLTE

Belite Bio initiated the NDA rolling submission to the FDA for Tinlarebant in Stargardt disease in April 2026, following the receipt of the Phase III clinical study report in Q1. The company is on track to complete the submission by Q2 2026. Management emphasized that FDA approval is the primary focus and will form the basis for submissions in other regions, with Japan approval anticipated within three months of FDA approval due to Sakigake Designation.

The company is actively building its commercial infrastructure in preparation for launch, including hiring for commercial leadership, sales, market access, and medical affairs teams. They plan to deploy two commercial teams, one focused on diagnostic promotion and disease awareness, and another on drug promotion, with a combined total of 30-40 team members. A comprehensive update on commercial planning, including patient numbers, is expected in September.

Enrollment has been completed for the Phase II/III DRAGON II clinical trial, evaluating Tinlarebant for Stargardt disease. This study enrolled 73 adolescents and adult subjects aged 12 to 20 years from Japan, the United States, and the U.K. While primarily a registration-enabling study for Japan, management noted that interim DRAGON II data could potentially serve as confirmatory evidence for FDA if required, though it is not currently believed to be applicable for U.S. filing.

Belite Bio is aiming for an interim analysis for its Geographic Atrophy (GA) program around the end of 2026. The company stated that the decision on resizing the study will be data-driven based on the interim results. Logistics for this trial are more complex due to the larger data set compared to the Stargardt disease studies.

Despite increased R&D and SG&A expenses in Q1 FY26, Belite Bio ended the quarter with a robust cash position of $799 million in cash, cash equivalents, and U.S. treasury bills, a higher balance than at the end of 2025. The company estimates a budget of approximately $300 million for the U.S. Stargardt launch and $150 million for the existing pipeline over the next three years, totaling $450 million, which is well-covered by current cash reserves.

Market research with payers has indicated strong support for the potential pricing range of Tinlarebant, recognizing the significant unmet need as the first treatment for Stargardt disease. While no final price has been set, management suggested a reference range of $350,000 to $500,000, aligning with average orphan drug prices in the U.S.